Lu Liu, Junsheng Chen, Yajie Deng, Fei Gao, Ting Lin, Zhijun Yang, Daijie Chen, Yu Yin
Contezolid, a novel oxazolidinone antibiotic, has comparable or superior antibacterial efficacy and safety to linezolid, now widely used for treating multidrug-resistant Gram-positive bacterial infections. Although numerous studies have investigated the immunomodulatory effects of oxazolidinone antibiotics, the immunomodulatory properties of contezolid remain poorly understood. This study aimed to investigate the anti‑inflammatory effects of contezolid using LPS-stimulated RAW264.7 macrophages. Experimental assessments demonstrated that contezolid significantly suppressed key inflammatory mediators, including nitric oxide and reactive oxygen species, while reducing IL-6 and TNF-α cytokine levels and CD86 concurrently. Functional analysis revealed attenuated phagocytic activity through fluorescence-based bacterial internalization assays and viable bacterial colony counting. Mechanistic studies using qRT-PCR identified transcriptional downregulation of Toll-like receptors, with TLR2 showing particularly pronounced suppression compared to activated controls. These findings indicate that, in addition to its known antimicrobial activity, contezolid also exhibits anti-inflammatory properties.
Zhang GXZ, et al. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment. Infection. 2024;52:787–800.
[DOI:
10.1007/s15010-024-02287-w]
Li B, et al. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment. Front Pharm. 2023;14:1157437.
[DOI:
10.3389/fphar.2023.1157437]
Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022;77:1762–9.
[DOI:
10.1093/jac/dkac073]
Zhao H, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.
[DOI:
10.1038/s41392-021-00658-5]
Gong T, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112.
[DOI:
10.1038/s41577-019-0215-7]
Kang E, et al. Regulation of anti-inflammatory and antioxidant responses by methanol extract of Mikania cordata (Burm. f.) B. L. Rob. leaves via the inactivation of NF-κB and MAPK signaling pathways and activation of Nrf2 in LPS-induced RAW 264.7 macrophages. Biomed Pharmacother. 2023;168:115746.
[DOI:
10.1016/j.biopha.2023.115746]
Tabara K, et al. Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent. J Antibiot. 2020;73:247–54.
[DOI:
10.1038/s41429-020-0278-5]
Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590.
[DOI:
10.1128/CMR.00078-09]
Premarathna AD, et al. Immunomodulation by xylan and carrageenan-type polysaccharides from red seaweeds: Anti-inflammatory, wound healing, cytoprotective, and anticoagulant activities. Int J Biol Macromol. 2024;260:129433.
[DOI:
10.1016/j.ijbiomac.2024.129433]
Wang Z, et al. Immunomodulatory peptides from thick-shelled mussel (Mytilus coruscus): Isolation, identification, molecular docking and immunomodulatory effects on RAW264.7 cells. Food Biosci. 2024;59:103874.
Lim JJ, Grinstein S, Roth Z. Diversity and versatility of phagocytosis: roles in innate immunity, tissue remodeling, and homeostasis. Front Cell Infect Microbiol. 2017;7:191.
[DOI:
10.3389/fcimb.2017.00191]
Fang W, et al. Identification and activation of TLR4-mediated signalling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Sci Rep. 2017;7:1663.
[DOI:
10.1038/s41598-017-01868-0]
Bode C, et al. Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis. J Antibiot. 2015;68:485–90.
[DOI:
10.1038/ja.2015.18]
